Structural Basis for the Development of Avian Virus Capsids That Display Influenza Virus Proteins and Induce Protective Immunity

ABSTRACT Bioengineering of viruses and virus-like particles (VLPs) is a well-established approach in the development of new and improved vaccines against viral and bacterial pathogens. We report here that the capsid of a major avian pathogen, infectious bursal disease virus (IBDV), can accommodate heterologous proteins to induce protective immunity. The structural units of the ∼70-nm-diameter T=13 IBDV capsid are trimers of VP2, which is made as a precursor (pVP2). The pVP2 C-terminal domain has an amphipathic α helix that controls VP2 polymorphism. In the absence of the VP3 scaffolding protein, 466-residue pVP2 intermediates bearing this α helix assemble into genuine VLPs only when expressed with an N-terminal His6 tag (the HT-VP2-466 protein). HT-VP2-466 capsids are optimal for protein insertion, as they are large enough (cargo space, ∼78,000 nm3) and are assembled from a single protein. We explored HT-VP2-466-based chimeric capsids initially using enhanced green fluorescent protein (EGFP). The VLP assembly yield was efficient when we coexpressed EGFP-HT-VP2-466 and HT-VP2-466 from two recombinant baculoviruses. The native EGFP structure (∼240 copies/virion) was successfully inserted in a functional form, as VLPs were fluorescent, and three-dimensional cryo-electron microscopy showed that the EGFP molecules incorporated at the inner capsid surface. Immunization of mice with purified EGFP-VLPs elicited anti-EGFP antibodies. We also inserted hemagglutinin (HA) and matrix (M2) protein epitopes derived from the mouse-adapted A/PR/8/34 influenza virus and engineered several HA- and M2-derived chimeric capsids. Mice immunized with VLPs containing the HA stalk, an M2 fragment, or both antigens developed full protection against viral challenge. IMPORTANCE Virus-like particles (VLPs) are multimeric protein cages that mimic the infectious virus capsid and are potential candidates as nonliving vaccines that induce long-lasting protection. Chimeric VLPs can display or include foreign antigens, which could be a conserved epitope to elicit broadly neutralizing antibodies or several variable epitopes effective against a large number of viral strains. We report the biochemical, structural, and immunological characterization of chimeric VLPs derived from infectious bursal disease virus (IBDV), an important poultry pathogen. To test the potential of IBDV VLPs as a vaccine vehicle, we used the enhanced green fluorescent protein and two fragments derived from the hemagglutinin and the M2 matrix protein of the human murine-adapted influenza virus. The IBDV capsid protein fused to influenza virus peptides formed assemblies able to protect mice against viral challenge. Our studies establish the basis for a new generation of multivalent IBDV-based vaccines.

[1]  E. Varečková,et al.  Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development , 2010, Virology Journal.

[2]  M. Bandehpour,et al.  Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus Challenge , 2012, PloS one.

[3]  C. Chou,et al.  Crystal structure of infectious bursal disease virus VP2 subviral particle at 2.6A resolution: implications in virion assembly and immunogenicity. , 2006, Journal of structural biology.

[4]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[5]  R. Varadarajan,et al.  Design of Escherichia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge , 2012, Journal of Virology.

[6]  B. Trus,et al.  Structural polymorphism of the major capsid protein of a double-stranded RNA virus: an amphipathic alpha helix as a molecular switch. , 2005, Structure.

[7]  B L Trus,et al.  The effects of radiation damage on the structure of frozen hydrated HSV-1 capsids. , 1993, Journal of structural biology.

[8]  S. Streatfield,et al.  Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development , 2012, Vaccine.

[9]  Z. Ku,et al.  Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms , 2013, Journal of Virology.

[10]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[11]  R. Wagner,et al.  Virus-like particles—universal molecular toolboxes , 2007, Current Opinion in Biotechnology.

[12]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[13]  M. Islam,et al.  Research on infectious bursal disease--the past, the present and the future. , 2003, Veterinary microbiology.

[14]  W. Fiers,et al.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011, The Journal of Immunology.

[15]  Javier Ortego,et al.  Antigen delivery systems for veterinary vaccine development , 2008, Vaccine.

[16]  R. Varadarajan,et al.  Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection , 2014, Proceedings of the National Academy of Sciences.

[17]  B. Chackerian,et al.  Virus-like particles: flexible platforms for vaccine development , 2007, Expert review of vaccines.

[18]  L. Dixon,et al.  Current strategies for subunit and genetic viral veterinary vaccine development. , 2011, Virus research.

[19]  B. Delmas,et al.  Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. , 2009, Vaccine.

[20]  B. Delmas,et al.  Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens. , 2004, Vaccine.

[21]  Marianne Manchester,et al.  Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[22]  J. Carrascosa,et al.  VP1, the Putative RNA-Dependent RNA Polymerase of Infectious Bursal Disease Virus, Forms Complexes with the Capsid Protein VP3, Leading to Efficient Encapsidation into Virus-Like Particles , 1999, Journal of Virology.

[23]  J Bernard Heymann,et al.  Bsoft: image processing and molecular modeling for electron microscopy. , 2007, Journal of structural biology.

[24]  J. Bárcena,et al.  Virus-like particles: The new frontier of vaccines for animal viral infections , 2012, Veterinary Immunology and Immunopathology.

[25]  Nicole F Steinmetz,et al.  Applications of viral nanoparticles in medicine. , 2011, Current opinion in biotechnology.

[26]  G. Rivas,et al.  Infectious bursal disease virus is an icosahedral polyploid dsRNA virus , 2009, Proceedings of the National Academy of Sciences.

[27]  J. Carrascosa,et al.  Different architectures in the assembly of infectious bursal disease virus capsid proteins expressed in insect cells. , 2000, Virology.

[28]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[29]  J. Pous,et al.  The 2.6-Angstrom Structure of Infectious Bursal Disease Virus-Derived T=1 Particles Reveals New Stabilizing Elements of the Virus Capsid , 2006, Journal of Virology.

[30]  W. Kowalczyk,et al.  Chimeric Infectious Bursal Disease Virus-Like Particles as Potent Vaccines for Eradication of Established HPV-16 E7–Dependent Tumors , 2012, PloS one.

[31]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[32]  M. Estes,et al.  Rotavirus virus-like particles administered mucosally induce protective immunity , 1997, Journal of virology.

[33]  Dr Ferdiye Taner,et al.  The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.

[34]  Irina Gutsche,et al.  The Birnavirus Crystal Structure Reveals Structural Relationships among Icosahedral Viruses , 2005, Cell.

[35]  J. Castón,et al.  The C-terminal domain of the pVP2 precursor is essential for the interaction between VP2 and VP3, the capsid polypeptides of infectious bursal disease virus. , 2004, Virology.

[36]  E. Mundt,et al.  Molecular and Structural Bases for the Antigenicity of VP2 of Infectious Bursal Disease Virus , 2007, Journal of Virology.

[37]  S. Elankumaran,et al.  A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV , 2004, Journal of Virology.

[38]  Jose A. Ruiz-Diaz,et al.  The Oligomerization Domain of VP3, the Scaffolding Protein of Infectious Bursal Disease Virus, Plays a Critical Role in Capsid Assembly , 2003, Journal of Virology.

[39]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[40]  Marco,et al.  Xmipp: An Image Processing Package for Electron Microscopy , 1996, Journal of structural biology.

[41]  W. Barclay,et al.  Influenza Pandemics , 2011, Advances in experimental medicine and biology.

[42]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[43]  J. Bárcena,et al.  Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses , 2016, Scientific Reports.

[44]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[45]  M. F. Boni,et al.  Vaccination and antigenic drift in influenza. , 2008, Vaccine.

[46]  A. Rynda-Apple,et al.  Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. , 2013, ACS nano.

[47]  M. Bachmann,et al.  Exploiting viral properties for the rational design of modern vaccines , 2008, Expert review of vaccines.

[48]  J. Bárcena,et al.  Design of novel vaccines based on virus-like particles or chimeric virions. , 2013, Sub-cellular biochemistry.

[49]  Bernd H. A. Rehm,et al.  Bionanotechnology : biological self-assembly and its applications , 2013 .

[50]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[51]  Noriko Kishida,et al.  Cross-Protective Potential of a Novel Monoclonal Antibody Directed against Antigenic Site B of the Hemagglutinin of Influenza A Viruses , 2009, PLoS pathogens.

[52]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[53]  J. Carrascosa,et al.  C Terminus of Infectious Bursal Disease Virus Major Capsid Protein VP2 Is Involved in Definition of the T Number for Capsid Assembly , 2001, Journal of Virology.

[54]  J. Carrascosa,et al.  Electrostatic Interactions between Capsid and Scaffolding Proteins Mediate the Structural Polymorphism of a Double-stranded RNA Virus* , 2009, The Journal of Biological Chemistry.

[55]  J. Lepault,et al.  The Last C-Terminal Residue of VP3, Glutamic Acid 257, Controls Capsid Assembly of Infectious Bursal Disease Virus , 2004, Journal of Virology.

[56]  J. Bárcena,et al.  Chimeric calicivirus-like particles elicit specific immune responses in pigs , 2012, Vaccine.

[57]  S. Schillberg,et al.  Protective Oral Vaccination against Infectious bursal disease virus Using the Major Viral Antigenic Protein VP2 Produced in Pichia pastoris , 2013, PloS one.

[58]  J A Lawton,et al.  Three-dimensional structural analysis of recombinant rotavirus-like particles with intact and amino-terminal-deleted VP2: implications for the architecture of the VP2 capsid layer , 1997, Journal of virology.

[59]  S. Plotkin,et al.  History of vaccine development , 2011 .

[60]  P. Alves,et al.  Virus-like particles in vaccine development , 2010, Expert review of vaccines.

[61]  Hiroshi Handa,et al.  Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. , 2014, Virology.

[62]  Jean Cohen,et al.  Individual Rotavirus-like Particles Containing 120 Molecules of Fluorescent Protein Are Visible in Living Cells* 210 , 2001, The Journal of Biological Chemistry.

[63]  J. Dubochet,et al.  Cryo-electron microscopy of vitrified specimens , 1988, Quarterly Reviews of Biophysics.

[64]  R. Gurny,et al.  Recent advances in mucosal immunization using virus-like particles. , 2013, Molecular pharmaceutics.

[65]  James R. Swartz,et al.  Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines , 2013, Proceedings of the National Academy of Sciences.

[66]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[67]  E. Engvall,et al.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. , 1971, Immunochemistry.